Clinical Trials Browser

Completed × INDUSTRY × CB-839 × Clear all

NCT03428217 2023-03-20

CANTATA

Phase 2 Completed

444 enrolled 15 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03057600 2022-09-28

Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)

Phase 2 Completed

52 enrolled 16 charts

Triple Negative Breast Neoplasms

NCT03965845 2022-09-19

A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors

Phase 1/2 Completed

Other solid neoplasmThoracic

Solid Tumors

NCT03163667 2022-09-15

ENTRATA

Phase 2 Completed

69 enrolled 12 charts

Carcinoma, Renal Cell

NCT02071862 2022-07-20

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Phase 1 Completed

BreastGenitourinaryOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Mesothelioma, Triple Negative Breast Neoplasms

NCT02071888 2018-07-18

Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors

Phase 1 Completed

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma

NCT02071927 2017-02-09

Study of the Glutaminase Inhibitor CB-839 in Leukemia

Phase 1 Completed

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma